ESR12: Léxane Fournier
|
Vertical Divider
Host Organization
Protein Engineering & Antibody Technologies, Merck Healthcare KGaA Supervisors Dr. Stefan Becker Dr. Lars Toleikis 
|
Identification of new targets from screening using biochemical and cell based assays Objectives:
1) Development of biochemical assays to detect allosteric inhibitors from screening. 2) Retrospect analysis of available in-house targets with known allosteric inhibition mechanism. 3) Expanded the methodology to new target classes with unknown allosteric mechanism in the ALLOstery in Drug Discovery framework of the consortium for medium to high throughput screening methods. Expected Results: 1) New biochemical assay platform for the medium to high throughput detection of allosteric inhibitors. 2) Validation of known allosteric inhibitors from biochemical screening. 3) Transfer of methodology to new target classes |
Brief Scientific Bio
Léxane Fournier began her studies by completing a bachelor’s degree in biochemistry at Clermont Auvergne University (Clermont-Ferrand, France). She then joined the master's program in biological engineering at Polytech Clermont, during which she performed two thesis projects. The first was carried out in collaboration with Ablynx NV (Ghent, Belgium). The second was held at Merck Healthcare KGaA (Vevey, Switzerland) and focused on cutting-edge technologies for cell line development. She also completed a master's degree in chemistry at Clermont Auvergne University. After her dual graduation, she joined the Protein Engineering and Antibody Technologies group at Merck Healthcare KGaA (Darmstadt, Germany) as an ESR as part of the ALLODD ITN project.
Léxane Fournier began her studies by completing a bachelor’s degree in biochemistry at Clermont Auvergne University (Clermont-Ferrand, France). She then joined the master's program in biological engineering at Polytech Clermont, during which she performed two thesis projects. The first was carried out in collaboration with Ablynx NV (Ghent, Belgium). The second was held at Merck Healthcare KGaA (Vevey, Switzerland) and focused on cutting-edge technologies for cell line development. She also completed a master's degree in chemistry at Clermont Auvergne University. After her dual graduation, she joined the Protein Engineering and Antibody Technologies group at Merck Healthcare KGaA (Darmstadt, Germany) as an ESR as part of the ALLODD ITN project.
|
|
This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 956314.
|
|